GPCRs have proven to be one of the most challenging targets for antibody drug development
| This week's Fierce LifeSci is brought to you by Twist Bioscience.
Trouble viewing? Click here.
|
| | Tuesday, September 14, 2021 | 2pm ET / 11am PT | |
|
|
| | | G protein-coupled receptors (GPCRs) are one of the most promising drug targets due to their pathophysiological role in the human body. However, at the same time, GPCRs have proven to be one of the most challenging targets for antibody drug development. In this webinar, we describe the use of next-generation DNA synthesis tools to overcome the DNA bottleneck in antibody-based GPCR drug discovery. Learn More. |
|---|
| |
|
|
| | | We will also describe the discovery and creation of both antagonistic and agonistic GLP-1R antibodies by panning this GPCR-focused phage display library on a GLP-1R overexpressing Chinese hamster ovary cell line. In addition, we demonstrate the in vitro and in vivo functional activity of the antibody candidates. |
|---|
| |
|
|
| | You are currently subscribed as newsletter@newslettercollector.com
If you no longer wish to receive promotions from Fierce LifeSciences, simply unsubscribe.
Refer to our Privacy Policy.
Fierce LifeSciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017
© 2021 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission. | |
|
|
